AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Your search for major depressive disorder returned 6 results
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial.
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.
The system is currently being assessed for its use in stroke rehabilition in the Phase 3 supplemental study ‘E-FIT’, involving 60 patients.
The likelihood of help or harm, also known as the risk/benefit ratio, was found to be more favorable for lithium.